MCB
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
MCB.00150-07v1
28/2/630    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.
Right arrow Articles by Harrison, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, M.
Right arrow Articles by Harrison, M. L.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, January 2008, p. 630-641, Vol. 28, No. 2
0270-7306/08/$08.00+0     doi:10.1128/MCB.00150-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

The SH3 Domain of Lck Modulates T-Cell Receptor-Dependent Activation of Extracellular Signal-Regulated Kinase through Activation of Raf-1{triangledown}

Manqing Li,1,{dagger} Su Sien Ong,1 Bartek Rajwa,2 Vivian T. Thieu,3,{ddagger} Robert L. Geahlen,1 and Marietta L. Harrison1*

Department of Medicinal Chemistry and Molecular Pharmacology,1 Purdue University Cytometry Laboratories Bindley Bioscience Center,2 Department of Biochemistry, Purdue University, West Lafayette, Indiana 479073

Received 25 January 2007/ Returned for modification 23 February 2007/ Accepted 25 October 2007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Engagement of the T-cell antigen receptor (TCR) results in the proximal activation of the Src family tyrosine kinase Lck. The activation of Lck leads to the downstream activation of the Ras/Raf/MEK/ERK signaling pathway (where ERK is extracellular signal-related kinase). Under conditions of weak, but not strong, stimulation through the TCR, a version of Lck that contains a single point mutation in the SH3 (Src homology 3) domain (W97ALck) fails to support the activation of ERK, despite initiating signaling through the TCR, as demonstrated by the robust activation of ZAP-70, PLC-{gamma}, and Ras. We determined that the signaling lesion in W97ALck-expressing cells lies at the level of Raf-1 activation and is dependent on the presence of tyrosines 340/341 in the Raf-1 sequence. These data demonstrate a second function for Lck in TCR-mediated signaling to ERK. Additionally, we found that a significant fraction of Lck is localized to the Golgi apparatus and that, compared with wild-type Lck, W97ALck displays aberrant Golgi membrane localization. Our results support a model where under conditions of weak stimulation through the TCR, in addition to activated Ras, Golgi apparatus-localized Lck is needed for the full activation of Raf-1.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The Src family tyrosine kinase Lck is essential for signaling through the T-cell receptor (TCR) complex (34). Along with family member Fyn, Lck initiates the signaling cascades emanating from a ligated TCR (16, 20, 22, 27, 32). Lck phosphorylates the immunoreceptor tyrosine-based activation motifs in {zeta}-subunits of the TCR, establishing binding sites for the SH2 (Src homology 2) domains of the tyrosine kinase ZAP-70. Once docked to phosphorylated immunoreceptor tyrosine-based activation motifs, ZAP-70 is phosphorylated and activated by Lck. ZAP-70 substrates include the transmembrane adaptor protein LAT. Phosphorylation of LAT generates a signaling platform for the subsequent activation of downstream signaling pathways, including the Ras/Raf-1/MEK/ERK signaling cascade (where ERK is extracellular signal-regulated kinase). In this well-accepted model of T-cell signaling, the only function of Lck is to initiate signaling from the TCR at the plasma membrane.

In studying the function of the SH3 domain of Lck, we noticed that a point mutant impairing the SH3 domain binding function of Lck (W97ALck) displayed aberrant intracellular trafficking (14). Denny et al. reported that cells expressing W97ALck failed to support activation of ERK following TCR ligation despite displaying normal ZAP-70 activation (8), suggesting a second role for Lck in mediating TCR-induced signaling to ERK. Other studies also suggested that Lck may serve additional roles in TCR-initiated signaling. In 1998, Wong et al. reported that a constitutively active ZAP-70/Syk chimera induced gene transcription in a TCR-independent manner in Lck-expressing Jurkat T cells but not in Lck-deficient J.CaM1 cells (38). We therefore wondered if this second putative function for Lck revealed by the W97A mutation was linked to the intracellular localization of Lck and what the mechanism was by which the kinase additionally was coupled to the activation of the ERK MAP kinase pathway.

Until recently, Ras activation was thought to occur solely on the cytosolic face of the plasma membrane. That view changed dramatically with the report by Chiu et al. demonstrating the activation of Ras isoforms on endoplasmic reticulum and Golgi membranes (3). Endomembrane-activated Ras was shown to couple to the ERK signaling cascade. Subsequently, it was demonstrated that Golgi membrane-associated Ras in T cells was activated through the PLC-{gamma}-dependent generation of diacylglycerol and activation of RasGRP1 (2). Most recently, using Jurkat T cells, Perez de Castro et al. reported that weak stimulation through the TCR resulted in the specific activation of N-Ras that was localized on Golgi membranes and that Golgi membrane-associated N-Ras activation coupled to ERK activation (29).

In order to identify the putative second function for Lck in the activation of the ERK signaling cascade, we systemically interrogated the activation of the known signaling molecules both upstream of ERK and downstream of the TCR in W97ALck-expressing cells. We report here that the inability of W97ALck to support ERK activation resulted from a defect in the activation of the serine/threonine kinase Raf-1. We further determined that the failure of W97ALck to support ERK activation was seen only under conditions of low threshold stimulation, conditions where Perez de Castro et al. reported that signaling to ERK was dependent on the activation of Golgi membrane-associated N-Ras. Finally, we found that, compared to that of wild-type Lck (WTLck), the association of W97ALck with the Golgi apparatus is diminished.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell cultures and transfection and establishment of stable cell lines. The human Jurkat T leukemia cell line (clone E6-1) and the Lck-deficient Jurkat mutant J.CaM1.6 were obtained from the American Type Culture Collection (ATCC). All cells were maintained at logarithmic growth at 37°C and 5% CO2 in RPMI 1640 medium supplemented with 7.5% fetal bovine serum, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, and 50 U/ml penicillin G and 50 µg/ml streptomycin. For transient transfections, DNA was introduced into cells by electroporation using a Cell-Porator (Life Technologies). J.CaM1.6 cells at a density of 4 x 105 to 6 x 105 cells/ml were harvested and resuspended in RPMI 1640 medium supplemented with only 7.5% fetal bovine serum to a final density of 1 x 107 cells/500 µl. For each transfection, 5 µg of Lck-enhanced green fluorescent protein (EGFP) DNA (WTLck or W97ALck) or 15 µg of myc-Raf-1 DNA was preincubated with 500 µl cell suspension at room temperature for 15 min. Electroporation was then performed at a setting of 800 µF, 250 V. After electroporation, the cells were kept at room temperature for 15 min and transferred into complete medium. Cells were harvested 24 to 36 h after transfection and prepared for further analysis. Jurkat cells were transfected with 20 µg of EGFP-N-Ras. J.CaM1.6 cell lines stably expressing either WTLck or the W97ALck mutant (14) were generated by cotransfecting cells with a pCAGGS plasmid containing either WTLck or W97ALck (15 µg DNA) and the pBabe-puro plasmid (5 µg DNA), which confers resistance to the antibiotic puromycin. Twenty-four hours following transfection, transfected cells were selected for growth in media containing 0.25 µg/ml puromycin for 14 days. Selected cells were screened for Lck expression by anti-Lck immunoblotting and cloned by limiting dilution. Cloned cell lines expressing either WTLck or W97ALck at similar levels were identified and used in the study. Equivalent TCR expression levels in all cell lines were verified by fluorescence-activated cell sorter (FACS) analysis (Purdue Cancer Center Analytical Cytology Facility). Experiments were conducted primarily using W97ALck clone D3.A2 and verified using W97ALck clone G2.B5 and W97ALck clone H6.B3.

Plasmids. Murine Lck cDNA was obtained from Andrey Shaw (Washington University) and subcloned into the pCAGGS vector (39) by use of EcoRI sites, resulting in the expression plasmid pCAGGS-Lck. The generation of pCDNA3-LckGFP constructs was described previously (14). The human Raf-1 cDNA sequence was subcloned from the construct p627 (ATCC 41050) into pCS2+MT, resulting in a plasmid (pCS2+MT-myc-Raf-1) encoding five copies of the myc tag followed by the human Raf-1 cDNA sequence. The myc-Raf-1 sequence was subcloned into pCAGGS by use of EcoRI sites, resulting in the expression plasmid pCAGGS-myc-Raf-1. The YY340/341FFRaf-1 mutant was generated using a Transformer site-directed mutagenesis kit (Clontech). All plasmids were verified by DNA sequencing. The pGEX-RBD vector, encoding the glutathione S-transferase (GST)-RBD (Ras-binding domain of Raf-1) fusion protein, was obtained from Elizabeth Taparowsky (Purdue University); the yellow fluorescent protein (YFP)-GalT and the EGFP-N-Ras vectors were obtained from Mark Philips (New York University School of Medicine); the pGEX-MEKKD vector, encoding the kinase-deficient GST-MEK fusion protein, was obtained from Curtis Ashendel (Purdue University); and the pGEX-CD3-{zeta} vector, encoding the GST-CD3-{zeta} fusion protein, was obtained from Janet Smith (GlaxoSmithKline).

Antibodies and reagents. Mouse anti-CD3-{varepsilon} antibody (UCHT1, NA/LE; BD Pharmingen) was used to ligate the TCR and to determine the TCR expression level by FACS analysis. The goat anti-mouse immunoglobulin G (IgG)-fluorescein isothiocyanate used in FACS analysis was purchased from Santa Cruz Biotechnology. Rabbit polyclonal anti-Lck antibody (2102; Santa Cruz Biotechnology) was used for anti-Lck immunoblotting. The rabbit polyclonal anti-Lck antiserum used in anti-Lck immunoprecipitations was described previously (28, 35). The anti-phospho-ZAP-70 (Tyr319) rabbit polyclonal antibody, anti-phospho-MEK1/2 (Ser217/221) rabbit polyclonal antibody, and anti-phospho-ERK1/2 (Thr202/Tyr204) rabbit polyclonal antibody were purchased from Cell Signaling Technology. The anti-phospho-Raf-1 (Ser338) mouse monoclonal antibody, anti-ZAP-70 rabbit polyclonal antibody, and mixed anti-PLC-{gamma}1 mouse monoclonal antibodies were from Upstate Biotechnology. The anti-Raf-1 mouse monoclonal antibody was from BD Transduction Laboratories. The anti-phospho-PLC-{gamma}1 (Tyr783) rabbit polyclonal antibody was from Biosource. The mouse anti-CD3-{zeta} antibody (6B10.2), anti-Raf-1 rabbit polyclonal antibody (C-12), anti-c-myc tag mouse monoclonal antibody (9E10), anti-MEK1 rabbit polyclonal antibody (12-B), anti-ERK1 rabbit polyclonal antibody (691), and anti-N-Ras mouse monoclonal antibody (sc-31) were purchased from Santa Cruz Biotechnology. The anti-pan-Ras mouse monoclonal antibody (Ab-3) was from Oncogene Research Products. The antiphosphotyrosine mouse monoclonal antibody (4G10) was purchased from Upstate Biotechnology. The antigiantin antibody was from Covance Research Products, Inc. Alexa Fluor 488-conjugated and Alexa Fluor 594-conjugated goat anti-mouse antibodies were purchased from Molecular Probes. Rhodamine-conjugated goat anti-rabbit IgG was purchased from Jackson ImmunoResearch. The Src family protein tyrosine kinase inhibitor PP2 was purchased from Calbiochem.

Cell stimulation. Cells in logarithmic growth were harvested and resuspended at 1.0 x 107 cells/ml in serum-free RPMI medium and placed on ice. Anti-CD3-{varepsilon} antibody was added at the indicated concentrations. Cells were incubated with the antibody on ice for 15 min, followed by a 3-min incubation at 37°C. Stimulated cells were returned to ice for 3 min prior to centrifugation at 180 x g for 10 min at 4°C. Pelleted cells were resuspended in 1% NP-40 lysis buffer (1% Nonidet P-40, 25 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1 mM sodium vanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml aprotinin and leupeptin, pH 7.4) and incubated on ice for 15 min. Lysates were cleared by centrifugation at 18,000 x g for 10 min at 4°C. Cell lysates were either boiled with equal volumes of sodium dodecyl sulfate (SDS) sample buffer (0.25 g/ml sucrose, 0.025 g/ml SDS, 25 mM Tris, 2.5 mM EDTA, 0.025 mg/ml pyronin Y, 5% 2-mercaptoethanol, pH 8.0) and resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) or left for further analysis.

Immunoblotting and immunoprecipitation. Protein samples were resolved by SDS-PAGE on 8% gels (or as otherwise specified) and transferred to polyvinylidene difluoride membranes (Immun-Blot PVDF; Bio-Rad). Membranes were blocked with 5% goat serum and incubated with primary antibody at room temperature for 1 to 2 h (or at 4°C overnight for phosphospecific antibodies), followed by incubation with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG. Membranes were developed using enhanced chemiluminescence reagents (ECL; Amersham Pharmacia Biotech) and autoradiography film. Quantitative immunoblotting was performed using a ChemiImager system (Alpha Innotech) or, where specified, using alkaline phosphatase-conjugated goat anti-mouse IgG+IgM (Amersham Pharmacia Biotech) and enhanced chemifluorescence (ECF; Amersham Pharmacia Biotech) and analyzed using a Molecular Dynamics Storm 860 imaging system.

For immunoprecipitations, cell lysates (in 1% NP-40 lysis buffer) were incubated with antibody and protein A-conjugated Sepharose 4B beads at 4°C for 2 h. After incubation, the beads were washed four times with prechilled 1% NP-40 lysis buffer and either boiled with SDS sample buffer and resolved by SDS-PAGE or left for further analysis.

In vitro Lck and Raf-1 kinase assays. Anti-Lck immunoprecipitates (polyclonal anti-Lck antibody [28, 35]) prepared from 1 x 107 cells were washed four times with prechilled 1% NP-40 lysis buffer and once with prekinase buffer (25 mM HEPES, 1 mM sodium vanadate, 20 µg/ml aprotinin and leupeptin, pH 7.4) and incubated with 5 µg GST-CD3-{zeta} fusion protein in 50 µl kinase assay buffer (25 mM HEPES, 1 mM sodium vanadate, 20 µg/ml aprotinin and leupeptin, 10 mM MnCl2, 5 µM ATP, 5 mM p-nitrophenyl phosphate, 20 µCi [{gamma}-32P]ATP/reaction, pH 7.4) at 30°C for the indicated times. The reactions were stopped by the addition of equal volumes of SDS sample buffer. The samples were boiled and resolved by SDS-PAGE, transferred to PVDF membranes, and quantified by using a Molecular Dynamics Storm 860 imaging system.

For Raf-1 kinase assays, exogenously expressed myc-Raf-1 was precipitated using anti-myc antibody (3 x 106 transfected cells/sample) and endogenous Raf-1 was precipitated using anti-Raf-1 rabbit polyclonal antibody (1 x 107 cells/sample). The Raf-1 immunoprecipitates were washed four times with prechilled 1% NP-40 lysis buffer and once with the prekinase buffer and incubated with 5 µg kinase-deficient GST-MEK fusion protein in 50 µl kinase assay buffer at 30°C for 20 min (myc-Raf-1) or 10 min (endogenous Raf-1), and the reactions were stopped by the addition of equal volumes of SDS sample buffer. Raf-1 kinase activity was analyzed following the same procedure as that for the Lck kinase activity.

ERK phosphatase assay. ERK phosphatase activity was determined as previously described, with minor modifications (19). Whole-cell lysates (80 µg/sample) prepared in 1% NP-40 lysis buffer (without phosphatase inhibitors, containing 10 µM MEK inhibitor U0126) were diluted 1:4 in phosphatase assay buffer (10 mM MgCl2, 10 mM HEPES, pH 7.4, and 10 µM MEK inhibitor U0126). Recombinant phosphorylated GST-ERK2 (Upstate Biotechnology) was added at 30 ng/sample and incubated for various times at room temperature. Samples were resolved by SDS-PAGE and transferred to PVDF membranes. The remaining amount of phosphorylated GST-ERK2 was determined by immunoblotting using antibodies against phospho-ERK1/2. Endogenous ERK2 was used as a protein loading control. The exposed film was developed using ECLplus and quantified using a Typhoon 9400 variable-mode imager and ImageQuant software (GE Healthcare Life Sciences). The data were analyzed using Microsoft Excel software and are expressed as the decrease in ERK phosphorylation as a function of time.

Ras activity assays. Cells (2.5 x 106) were lysed in 500 µl Mg2+-containing lysis buffer (1% Nonidet P-40, 25 mM HEPES, 150 mM NaCl, 0.25% sodium deoxycholate, 10% glycerol, 10 mM MgCl2, 1 mM EDTA, 1 mM sodium vanadate, 10 mM NaF, 20 µg/ml aprotinin and leupeptin, pH 7.4) on ice. The lysates were cleared by centrifugation at 18,000 x g for 10 min at 4°C. The supernatants were mixed with GST-RBD fusion protein (10 µg/sample) bound to glutathione-Sepharose 4B beads for 30 min at 4°C. The beads were collected and washed with prechilled Mg2+-containing lysis buffer three times. The samples were boiled with SDS sample buffer, resolved by SDS-PAGE on 12% gels, and transferred to PVDF membranes. Membranes were blotted with anti-pan-Ras antibody and quantified.

Fluorescence microscopy. J.CaM1.6 cells were transiently transfected with either WTLck-EGFP or W97ALck-EGFP. The data in Fig. 8B were visualized by fluorescence microscopy as previously described (23). All other image collections and analyses were performed in the Purdue University Cytometry Laboratory (see below). Jurkat cells were transiently transfected with YFP-GalT as described above. For all immunofluorescence studies, cells were washed with phosphate-buffered saline and overlaid onto poly-L-lysine-coated coverslips (100 µg/ml). Cells were fixed with 3.7% formaldehyde solution for 10 min. For indirect immunostaining, cells were incubated with blocking buffer (10% goat serum in phosphate-buffered saline), followed by incubation with primary antibody overnight at 4°C and then with Alexa Fluor 488-conjugated or Alexa Fluor 594-conjugated goat anti-mouse IgG or rhodamine-conjugated goat anti-rabbit IgG. Images were collected on a Nikon e1000 fluorescence microscope, and confocal analysis was performed with a Bio-Rad 2100 MP multiphoton microscope in the Purdue University Cytometry Laboratories in the Bindley Biosciences Center. All images were captured using identical camera settings. Image processing was performed using Image Pro-Plus package 6.2 (Media Cybernetics, Silver Spring, MD). The statistical data analysis and plots were prepared using R, a public-domain computer language and programming environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria). Image analysis was performed by segmenting the rhodamine channel (giantin) and using it as a mask to extract the Golgi membrane regions in the GFP channel (LckGFP). The segmentation threshold was constant for all images and was determined experimentally. The outline of the cells was found by binary segmentation of green-channel images. The extracted binary masks were smoothed using morphological filters (opening and closing filter with a 5 by 5 octagonal kernel). The background of the green images was flattened and removed by fitting a two-dimensional polynomial before segmentation. To eliminate the contribution of autofluorescence, cells that contained less than 50 arbitrary units/pixel were excluded from the analysis. Mann-Whitney analysis was performed to determine the ratio of GFP fluorescence intensity associated with the Golgi body to the total fluorescence intensity of the cell.


Figure 8
View larger version (26K):
[in this window]
[in a new window]

  		FIG. 8. Reduced colocalization of W97ALck with Golgi apparatus-associated N-Ras. (A) J.CaM1.6 cells were transiently transfected with the indicated GFP constructs, fixed and stained with antibodies to N-Ras, and visualized by fluorescence microscopy. The images are representative of a population of cells. (B) Fluorescence images of J.CaM1.6 cells stably expressing either WTLck or W97ALck were fixed and costained with antibodies to giantin (cis-medial Golgi apparatus marker) and N-Ras. The relative ratio of Golgi apparatus-localized N-Ras fluorescence to total cell fluorescence was calculated and graphed as the mean of Golgi apparatus-localized N-Ras (n = 18).

 

   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Generation of cell lines stably expressing either WTLck or W97ALck. WTLck and a point mutant crippling the binding capability of the SH3 domain (W97ALck) were expressed in the Lck-deficient cell line J.CaM1.6, a derivative of the human leukemia T-cell line Jurkat (12, 34). Several stable cell lines expressing similar levels of WTLck and W97ALck were isolated (Fig. 1A) and analyzed for TCR expression by flow cytometry (Fig. 1B). The expression level of WTLck and W97ALck was approximately one-fifth of the level of Lck present in parental Jurkat cells (Fig. 1A). We found that the widely used anti-Lck mouse monoclonal antibody clone 3A5 (Santa Cruz Biotechnology, Inc.) poorly recognized W97ALck in immunoblotting protocols (data not shown). Therefore, a rabbit polyclonal antibody was used throughout this study. Cell lines expressing similar levels of WTLck or W97ALck and equivalent levels of TCR were chosen for further study.


Figure 1
View larger version (25K):
[in this window]
[in a new window]

  		FIG. 1. Stable cell lines expressing WTLck or W97ALck. (A) Cell lysates from Jurkat (5 x 105 cells), J.CaM1.6 (2.5 x 106 cells), and generated W97ALck (2.5 x 106 cells) cell lines were assayed for Lck expression by immunoblot analysis using anti-Lck polyclonal antibodies. (B) TCR expression level was determined by staining cells with anti-CD3-{varepsilon} mouse monoclonal antibody followed by goat anti-mouse IgG-fluorescein isothiocyanate secondary antibody. Stained cells were analyzed by flow cytometry. Control cells were stained with secondary antibody in the absence of the primary antibody.

 
TCR-induced ERK and MEK activation were reduced in W97ALck-expressing cells. In agreement with results originally reported by Denny et al. (8), we found that cells expressing W97ALck failed to support the activation of ERK following TCR ligation (Fig. 2A). Additionally, however, we found that this failure was critically dependent on the level of stimulation through the TCR. At high concentrations of anti-TCR stimulating antibody, the activation of ERK in W97ALck-expressing cells was similar to that seen in cells expressing WTLck. At lower concentrations of stimulating antibody, however, loss of binding though the SH3 domain of Lck had a profound effect on ERK activation. W97ALck cells, however, showed normal activation following stimulation with phorbol myristate acetate (data not shown). As shown in Fig. 2A, a similar but less dramatic result was obtained when the activity of MEK was measured. These results were obtained with three independently derived W97ALck-expressing cell lines (Fig. 2B). One potential explanation for the decreased ERK MAP kinase activity in W97ALck-expressing cells was that these cells contained elevated dephosphorylating activity toward ERK MAP kinase. This does not seem to be the case, as, if anything, there appeared to be a slight decrease in phosphatase activity toward exogenous phospho-ERK MAP kinase in cell lysates from W97ALck-expressing cells compared with the activity in lysates from cells expressing WTLck (Fig. 2C).


Figure 2
View larger version (76K):
[in this window]
[in a new window]

  		FIG. 2. Decreased activation of ERK1/2 and MEK1/2 in cell lines expressing W97ALck. (A) WTLck (WT)- and W97ALckD3.A2 (97A)-expressing cells were incubated with the indicated concentrations of anti-CD3-{varepsilon} antibody. Cell lysates were assayed for the presence of phosphorylated ERK1/2 by immunoblotting using anti-phospho-ERK1/2 antibody (top panel) and phosphorylated MEK1/2 by immunoblotting using anti-phospho-MEK1/2 antibody (third panel). The membranes were stripped and reprobed with anti-ERK1/2 antibody (second panel) and anti-MEK1/2 antibody (bottom panel) to confirm equal loading of samples. The activation of ERK1/2 and MEK1/2 was determined in separate experiments. The experiments were repeated three times with similar results. Pixel intensities were determined by NIH Image J software and were normalized to maximal activated ERK or MEK. (B) Three independently derived cell lines expressing W97ALck as well as cells expressing WTLck were incubated in the absence (–) or presence (+) of anti-CD3-{varepsilon} antibody (1 µg/ml). The phosphorylation of ERK1/2 was determined as described above. The experiment was repeated three times with similar results. (C) WTLck- and W97ALck-expressing cells were stimulated with 1 µg/ml anti-CD3-{varepsilon} antibody. Whole-cell lysates were assayed for phosphatase activity for the indicated times by use of phosphorylated GST-ERK2 as an exogenous substrate, followed by anti-phospho-ERK1/2 immunoblotting (bottom panel). Data were corrected for endogenous ERK2 levels (loading control, top panel) and are presented graphically. The data are the averages of three independent experiments. mAb, monoclonal antibody.

 
The Lck substrates CD3-{zeta} and ZAP-70 were constitutively tyrosine phosphorylated in cells expressing W97ALck. Another possible explanation for the failure of W97ALck to support the activation of ERK was that the kinase activity of W97ALck was impaired. We considered this unlikely since structural studies predict that disruption of the intramolecular binding of the SH3 domain would actually activate kinase activity. In fact, it had been reported that W97ALck did indeed exhibit increased catalytic activity (8). W97ALck immunoprecipitated from W97ALckD3.A2 cells showed a kinase activity similar to that of immunoprecipitated WTLck (Fig. 3A). Despite the similar in vitro kinase activities, cells expressing W97ALck contained constitutively elevated levels of tyrosine-phosphorylated Lck substrates CD3-{zeta} and ZAP-70 (Fig. 3B and C). The constitutively high level of ZAP-70 tyrosine phosphorylation was further increased following TCR engagement (Fig. 3C and D). Elevated levels of tyrosine-phosphorylated ZAP-70 were seen in three independently derived cell lines expressing W97ALck (Fig. 3D). The elevation in the constitutive tyrosine phosphorylation of CD3-{zeta} in W97ALck-expressing cells was abolished when the cells were incubated in the presence of the Src family kinase inhibitor PP2 (Fig. 3B). These results indicated that the failure of W97ALck to support ERK activation was not because the mutant failed to initiate signaling through the TCR. Rather, they revealed that in addition to activating signaling through the TCR, Lck was needed at a step distal to the phosphorylation and activation of ZAP-70.


Figure 3
View larger version (51K):
[in this window]
[in a new window]

  		FIG. 3. W97ALck displays increased catalytic activity in cells. (A) WTLck and W97ALck from unstimulated cells were immunoprecipitated and incubated with GST-CD3-{zeta} in the presence of [{gamma}-32P]ATP for the indicated times. The reaction mixtures were resolved by SDS-PAGE and transferred to a PVDF membrane, and phosphorylation was detected (left) and quantified (right) using a Storm 860 phosphorimager. Arbitrary units of activity are shown in the right panel. (B) Untransfected J.CaM1.6 cells or J.CaM1.6 cells expressing either WTLck or W97ALck were preincubated in the absence (–) or the presence (+) of the Src family kinase inhibitor PP2 (10 µM) at 37°C for 30 min. CD3-{zeta} was immunoprecipitated (I.P.) from cell lysates and resolved by SDS-PAGE. Following transfer to a PVDF membrane, the tyrosine phosphorylation of CD3-{zeta} was detected by immunoblotting (I.B.) using the antiphosphotyrosine antibody 4G10 (top). The membrane was stripped and reprobed with anti-CD3-{zeta} antibody to confirm equal levels of immunoprecipitation of CD3-{zeta} (bottom). (C) WTLck (WT)- and W97ALck (97A)-expressing cells were stimulated with the indicated concentrations of anti-CD3-{varepsilon} antibody. The tyrosine phosphorylation of ZAP-70 in cell lysates was determined using anti-phospho-ZAP-70 antibody (top). The membrane was stripped and reprobed with anti-ZAP-70 antibody to confirm equal loading of samples (bottom). (D) Independently derived W97ALck-expressing cell lines and cells expressing WTLck were incubated in the absence (–) or presence (+) of anti-CD3-{varepsilon} antibody (1 µg/ml), and the phosphorylation of ZAP-70 in cell lysates was determined by immunoblotting using anti-phospho-ZAP-70 antibody (top). The membrane was stripped and reprobed with anti-ZAP-70 antibody to confirm equal loading of samples (bottom). mAb, monoclonal antibody.

 
Tyrosine phosphorylation of PLC-{gamma}1 was elevated in W97ALck-expressing cells. Following TCR engagement, activated ZAP-70 phosphorylates tyrosine residues on the membrane-bound adapter protein LAT, creating a binding site for the SH2 domain of PLC-{gamma}1. Membrane-recruited PLC-{gamma}1 is phosphorylated and activated by both ZAP-70 and Itk. To determine whether the lesion in the activation of the ERK pathway that was seen in cells expressing W97ALck was at the level of phosphorylation of PLC-{gamma}1 on tyrosine, we immunoblotted lysates of activated cells by using antibody recognizing phospho-Y783, which is phosphorylated in active PLC-{gamma}1 (18, 21). As can be seen in Fig. 4A, like CD3-{zeta} and ZAP-70, the tyrosine phosphorylation of PLC-{gamma}1 was constitutively elevated in cells expressing W97ALck relative to the level in cells expressing WTLck. This level was further enhanced following TCR engagement with concentrations of anti-CD3-{varepsilon} antibody that failed to trigger the activation of ERK in cells expressing W97ALck. These results indicated that the additional step in the ERK pathway where Lck is needed lay downstream of ZAP-70 and PLC-{gamma}1.


Figure 4
View larger version (33K):
[in this window]
[in a new window]

  		FIG. 4. Tyrosine phosphorylation of PLC-{gamma}1 and activation of Ras following TCR engagement are enhanced in W97ALck-expressing cells. (A) WTLck- and W97ALck-expressing cells were incubated in the absence (–) or presence (+) of anti-CD3-{varepsilon} antibody (1 µg/ml). The phosphorylation of PLC-{gamma}1 at Y783 was detected by immunoblotting cell lysates with anti-phospho-PLC-{gamma}1 (Y783) antibody (top). The membrane was stripped and reprobed with anti-PLC-{gamma}1 antibody to confirm equal loading of samples (bottom). (B) WTLck (WT)- and W97ALck (97A)-expressing cells were incubated in the presence of the indicated concentrations of anti-CD3-{varepsilon} antibody. The GTP-bound active form of Ras was precipitated from cell lysates by use of a GST-Raf-1-RBD fusion protein bound to glutathione-linked Sepharose beads. Precipitated Ras was detected by immunoblotting using anti-pan-Ras antibodies (top). The membrane was stripped and reprobed using antibodies specific for N-Ras (middle). Cell lysates from the same samples were immunoblotted with anti-pan-Ras antibody (bottom). Ras activation was quantified by using a ChemiImager system (histogram). mAb, monoclonal antibody.

 
Ras activation following TCR ligation was normal in cells expressing W97ALck. In T lymphocytes, the major pathway for the activation of Ras is through RasGRP, a guanine nucleotide exchange factor that is recruited and activated by diacylglycerol, a product of PLC-{gamma}1. To test the integrity of Ras activation following TCR ligation in W97ALck-expressing cells, we examined cell lysates for the presence of activated Ras by using RBD pull-down assays. As can be seen in Fig. 4B, at levels of anti-TCR stimulating antibody where ERK activation is not supported in W97ALck-expressing cells, levels of activated Ras were normal. When the immunoblot shown in the top panel of Fig. 4B was stripped and reprobed with antibodies to the N-Ras isoform of Ras, it was found that under the stimulation conditions used in this study N-Ras was activated and that the extent of activation in WTLck-expressing cells was similar to that in W97ALck-expressing cells (Fig. 4B, second panel). These results indicated that the second, distal site in the ERK pathway where Lck is needed was likely to be downstream of Ras.

Raf-1 activation was impaired in cells expressing W97ALck. Following TCR engagement, the activation of Ras results in the membrane recruitment and activation of Raf-1, which, in turn, phosphorylates and activates MEK1/2, the upstream activator of ERK1/2. To test whether the activation of Raf-1 was impaired in cells expressing W97ALck, a myc-Raf-1 fusion protein was transiently expressed in the WTLck- and W97ALck-expressing cell lines. Following stimulation through the TCR, myc-Raf-1 was immunoprecipitated and tested for kinase activity in an in vitro kinase assay using kinase-deficient GST-MEK as a substrate. As shown in Fig. 5A, the ability of W97ALck-expressing cells to activate myc-Raf-1 was significantly reduced relative to that of cells expressing WTLck. To verify that this result was not a function of Raf-1 overexpression, the activity of endogenous Raf-1 was measured in WTLck- and W97ALck-expressing cells and similar results were obtained (Fig. 5B). Since the activation of Ras was fully supported by W97ALck, it was likely that the recruitment of Raf-1 to the membrane occurred normally in W97ALck-expressing cells. This led to the hypothesis that the lesion in W97ALck-expressing cells resulted from an inability of membrane-bound Raf-1 to be fully activated.


Figure 5
View larger version (68K):
[in this window]
[in a new window]

  		FIG. 5. Lck regulates the activation of Raf-1 following TCR engagement through phosphorylation of Y340/Y341. (A) Myc-tagged Raf-1 was transiently expressed in WTLck- and W97ALck-expressing cells. Cells were stimulated with anti-CD3-{varepsilon} antibody (+) (4 µg/ml) or left untreated (–). Myc-Raf-1 was immunoprecipitated from cell lysates by use of anti-myc antibody and incubated with a GST-tagged kinase-dead version of MEK [GST-MEK(KD)] and [{gamma}-32P]ATP. Samples were resolved by SDS-PAGE, transferred to PVDF membranes, and analyzed by autoradiography (left). The kinase activity of myc-Raf-1 from three independent experiments was determined and expressed relative to the activity of myc-Raf-1 in resting WTLck-expressing cells (right). (B) J.CaM1.6 cells expressing either WTLck or W97ALck were stimulated with anti-CD3-{varepsilon} antibody (+) (1 µg/ml) or left untreated (–). Endogenous Raf-1 was immunoprecipitated using anti-Raf-1 antibody and assayed for kinase activity as described above. (C) Myc-tagged wild-type Raf-1 (WTRaf-1) or a myc-tagged YY340/341FF Raf-1 mutant (FFRaf-1) was transiently expressed in Jurkat cells. Cells were stimulated with anti-CD3-{varepsilon} antibody (4 µg/ml) or left untreated. Myc-Raf-1 was assayed for kinase activity as described above. (D) Myc-tagged YY340/341FF Raf-1 (Myc-FFRaf-1) was transiently expressed in J.CaM1.6 cells expressing either WTLck or W97ALck. Cells were stimulated with anti-CD3-{varepsilon} antibody (4 µg/ml) or left untreated. The YY340/341FF mutant Myc-Raf-1 was assayed for kinase activity as described above. mAb, monoclonal antibody.

 
W97ALck fails to support the phosphorylation of Raf-1. Although the mechanism of activation of Raf-1 is complex and involves several phosphorylation events and sites, mutational studies show that phosphorylation at tyrosine 340/341 and serine 338 is a prerequisite for full activation of Raf-1 in fibroblasts (11, 17, 25). Consistent with the current model of Raf-1 activation, a Raf-1 construct in which phenylalanines were substituted for tyrosines 340 and 341 (FFRaf-1) showed significantly reduced activity following TCR ligation compared to that of Raf-1 (Fig. 5C). However, the activation of FFRaf-1 was not completely abolished. We reasoned that if the lesion in the activation of the ERK pathway in W97ALck-expressing cells was due to a failure of Raf-1 phosphorylation at tyrosines 340 and 341, then the tyrosine 340/341-independent activation of FFRaf-1 should not be compromised in W97ALck-expressing cells. This was indeed the case, as demonstrated in Fig. 5D.

Prior phosphorylation of Y340/Y341 is necessary for activation-induced phosphorylation of S338 in Raf-1. Phosphorylation of S338 positively regulates the activation of Raf-1 (4, 9). Mutation of Raf-1 Y341 to phenylalanine blocks the phosphorylation of S338 when Raf-1 is activated by coexpression with oncogenic Ras and active Src but not when Raf-1 is activated by stimulation of the epidermal growth factor receptor (25). To test if the prior phosphorylation of Y340 and/or Y341 was required for the phosphorylation of S338 following TCR engagement, we transiently expressed wild-type Raf-1 or FFRaf-1 in the WTLck-expressing J.CaM1.6 cells. The cells were stimulated through the TCR and tested for Raf-1 S338 phosphorylation by use of an antibody specific to phospho-S338. As seen in Fig. 6A, the TCR-induced phosphorylation of S338 in FFRaf-1 relative to that in wild-type Raf-1 was severely impaired, suggesting that the TCR-induced phosphorylation of Raf-1 on S338 largely depends on the prior phosphorylation of Y340/Y341. If, as our data suggested, the Lck SH3 domain mutation impairs the phosphorylation of Y340/Y341, we reasoned that the phosphorylation of S338 would be reduced significantly in cells expressing W97ALck. To test this, we stimulated cells expressing either WTLck or W97ALck and measured the phosphorylation of S338 by immunoblotting. As suspected, the phosphorylation of S338 of Raf-1 in the W97ALck-expressing cells was defective compared to that in WTLck-expressing cells (Fig. 6B).


Figure 6
View larger version (50K):
[in this window]
[in a new window]

  		FIG. 6. Raf-1 Ser338 phosphorylation following TCR engagement is dependent on the prior phosphorylation of Tyr340/Tyr341. (A) Myc-tagged wild-type Raf-1 (WTRaf-1) or a myc-tagged YY340/341FF Raf-1 mutant (FFRaf-1) was transiently expressed in J.CaM1.6 cells expressing WTLck. Cells were stimulated with anti-CD3-{varepsilon} antibody (+) (1 µg/ml) or left untreated (–). The phosphorylation of either WTRaf-1 or FFRaf-1 at Ser338 was detected by immunoblotting whole-cell lysates using anti-phospho-Raf-1 (Ser338) antibody. The membrane was stripped and reprobed with antibodies to Raf-1 to verify equal loading of samples. (B) Three independent clones of J.CaM1.6 cells expressing W97ALck as well as cells expressing WTLck were stimulated with anti-CD3-{varepsilon} antibody (+) (1 µg/ml) or left untreated (–). The phosphorylation of endogenous Raf-1 at Ser338 was determined as described above. mAb, monoclonal antibody.

 
Trafficking of Lck through the Golgi apparatus. One of the major phenotypic differences between J.CaM1.6 cells expressing WTLck and those expressing W97ALck is that the SH3 domain mutant demonstrates an aberrant intracellular localization (14). As shown in Fig. 7A (top left), in addition to its presence at the plasma membrane, WTLck was found localized at an intracellular structure containing giantin, a marker for the cis-medial Golgi apparatus. In contrast, however, a significantly reduced amount of W97ALck appeared to colocalize with giantin (Fig. 7A, bottom left). Golgi apparatus-associated Lck was also seen in the parental Jurkat cells, where Lck was found to colocalize with both giantin and YFP-1,4-galactosyltransferase (GalT), a marker for the trans-Golgi apparatus (Fig. 7B). In addition, we analyzed 43 Jurkat cells and found that the mean value of fluorescence from Golgi apparatus-associated Lck as a proportion of total cellular Lck was 0.18 ± 0.02, indicating that approximately 18% of Lck is localized to the Golgi apparatus in Jurkat cells (data not shown). We next investigated whether the intracellular distribution of either WTLck or W97ALck changed following stimulation through the TCR and found that there was no significant redistribution of either WTLck or W97ALck following low-grade stimulation (Fig. 7A, left).


Figure 7
View larger version (27K):
[in this window]
[in a new window]

  		FIG. 7. W97ALck displays decreased localization to the Golgi apparatus. (A) J.CaM1.6 cells transiently transfected with the indicated Lck-GFP constructs were either unstimulated or stimulated with {alpha}-CD3 antibodies. Cells were fixed and stained with antibodies to giantin (rhodamine) and visualized by fluorescence microscopy. Fifty-nine W97ALckGFP- and 103 WTLckGFP-expressing cells were analyzed. The median total fluorescence intensity for WTLckGFP-expressing cells was (5.42 ± 1.87) x 105 arbitrary units (AUs) and that for W97ALckGFP-expressing cells was (4.88 ± 2.51) x 105 AUs, indicating that expression levels of the two constructs were similar. The distribution of the fluorescence intensity both for WTLckGFP-expressing cells and for W97ALckGFP-expressing cells was non-Gaussian and therefore the quantified data are represented by a Tukey box plot (right). Mann-Whitney analysis was used to generate the Tukey box plot (P < 0.05). The median ratio of fluorescence intensity (Golgi apparatus-associated Lck to total cellular Lck) for WTLck was 0.201 ± 0.026 and that for W97ALck was 0.142 ± 0.025. The bars in the Tukey box plot demarcate the 75th percentile and the 25th percentile, respectively. (B) (Top) Jurkat cells were fixed and costained using antibodies to Lck (Alexa Fluor 488, green) and giantin (cis-medial Golgi apparatus, rhodamine). (Bottom) Jurkat cells were transiently transfected with YFP-GalT (trans-Golgi apparatus marker). After 24 h, cells were fixed and stained for Lck (Alexa Fluor 594, red) and visualized by fluorescence confocal microscopy.

 
The demonstration that Lck colocalizes with markers for the Golgi apparatus coupled with the findings described by Perez de Castro et al. (29) predicted that a portion of intracellular Lck would colocalize with Golgi apparatus-associated N-Ras. In order to determine whether W97ALck localized less readily with Golgi apparatus-associated N-Ras, J.CaM1.6 cells expressing W97ALck-GFP or WTLck-GFP were immunostained for N-Ras. As can be seen in Fig. 8A, considerably less W97ALck than WTLck was observed to colocalize with N-Ras on the Golgi apparatus, despite equal levels of Golgi apparatus-associated N-Ras in WTLck- and W97ALck-expressing cells (Fig. 8B). This is consistent with the results shown in Fig. 7 demonstrating a reduced colocalization of W97ALck with giantin.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In studying the function of the SH3 domain of Lck, we, along with Denny et al. (8), noticed a defect in the TCR-stimulated activation of ERK that could not be explained by Lck's canonical role of initiating signaling from the receptor. Our results show that the failure of Lck to support ERK activation when it harbors a mutation that disrupts binding through its SH3 domain (W97ALck) is dependent on the concentration of stimulating anti-CD3 antibody. Signaling is normal at high doses of stimulating antibody but is impaired dramatically at lower concentrations. However, the initiation of T-cell signaling as measured by the phosphorylation of CD3-{zeta} and the phosphorylation and activation of ZAP-70 and PLC-{gamma} actually is elevated in cells expressing W97ALck. Thus, under conditions of weak stimulation, it appears that Lck is needed for the activation of ERK at a step distal to the initiation of T-cell signaling. An intact SH3 domain is critical for this second, downstream function of Lck. The notion that Lck is needed at a step distal to ZAP-70 activation was raised by Wong et al. (38), who reported that the expression of a constitutively active ZAP-70/Syk chimera in Lck-deficient J.CaM1.6 cells failed to rescue ERK-dependent downstream signaling events.

To identify this putative second step, we undertook a systematic investigation into the lesion responsible for the failure of W97ALck to activate ERK and identified a defect in the activation of the serine/threonine kinase Raf-1. The regulation of the kinase activity of Raf-1 is remarkably complex and involves phosphorylation on at least four activating sites and six inactivating sites (1, 5, 10, 15, 36, 40). One mechanism by which Raf-1 is activated is through the actions of Src family protein tyrosine kinases. In T cells, extracellular engagement of the transmembrane Lck binding partner CD4 results in the association of Lck and Raf-1 (30). When Raf-1 is coexpressed with Lck in Sf9 cells, Raf-1 becomes prominently tyrosine phosphorylated and displays elevated kinase activity (11). Coexpression studies and in vitro kinase assays identified Y340 and Y341 as the prominent sites on Raf-1 phosphorylated by Src family kinases (6, 11, 17, 24, 25, 33, 37). Consequently, substitution of Y340 and Y341 with phenylalanines impairs the activation of Raf-1 in a variety of systems (4, 9, 24, 25, 33). Our data indicate that, under conditions of weak TCR stimulation, the Lck-mediated tyrosine phosphorylation of Raf-1 is a prerequisite for its phosphorylation on S338, which is needed for its full activation for optimized signaling to ERK. Under conditions of strong TCR stimulation, the robust activation of proximal TCR signaling events in W97ALck-expressing cells may compensate for the signaling defect caused by the lack of a functional SH3 domain in Lck.

The importance of the Lck SH3 domain in the activation of the ERK pathway in vivo recently has been demonstrated. Rudd et al. reported that thymocytes from mice expressing W97ALck in place of normal Lck display an impaired activation of ERK despite supporting the strong activation of ZAP-70 following stimulation through the TCR (31). This phenotype is identical to the phenotype we observed for W97ALck-expressing cells. Thus, in the context of the whole animal, the SH3 domain of Lck also is critical for the full activation of the ERK pathway in response to signals generated through the TCR. The signaling lesion induced by crippling the SH3 domain of Lck resulted in defects in early thymocyte development and maturation of single positive lineages (31). Thus, the cellular pathways that lead to the activation of ERK appear to be critical for T-cell development, and the SH3 domain of Lck is a major contributor to this regulation in vivo. Our data extend this observation to show that this contribution is made through the activation of Raf-1.

Recently, it has been appreciated that the kinetics of ERK activation are greatly influenced by the subcellular localization of the Ras signaling cassette (13, 26). In 2002, Chiu et al. discovered that the acylated isoforms of Ras became activated on Golgi membranes and this activation resulted in downstream signaling to ERK (3). Thus, both H- and N-Ras were demonstrated to be activated on the Golgi membranes in response to growth factor stimulation (epidermal growth factor) and the Golgi membrane-localized activation was found to be dependent on the activity of Src family kinases. More recently, Perez de Castro et al. demonstrated that in Jurkat T cells, low-grade stimulation through the TCR resulted in the specific activation of Golgi membrane-associated N-Ras, which coupled to the downstream activation of ERK (29).

Although abrogating binding through the SH3 domain of Lck does not significantly affect its catalytic activity, it does have significant effects on the cellular localization of Lck. W97ALck localizes predominately to detergent-insoluble, lipid raft membrane fractions, whereas WTLck is approximately evenly distributed between detergent-soluble and detergent-insoluble fractions (14). The predominant localization to lipid rafts exhibited by the Lck SH3 domain mutant correlated with an increased rate of turnover of palmitic acid (14). Therefore, it is reasonable to suggest that the signaling defect observed in W97ALck-expressing cells may be a result of the membrane mislocalization of the Lck SH3 domain mutant. In this regard, Daniels et al. very recently reported that the threshold of thymic selection is mediated by the cellular localization of the ERK signaling cassette (7). Thymocytes stimulated with high-affinity peptides induced efficient activation of ZAP-70, strong and sustained tyrosine phosphorylation of LAT, the total recruitment of Ras and Raf-1 to the plasma membrane, and negative selection. Weaker TCR peptides induced lower levels of ZAP-70 activation, weaker and delayed LAT tyrosine phosphorylation, recruitment of Ras and Raf-1 to the Golgi membrane, and positive selection. Thus, the localization of the active ERK cassette including Ras and Raf-1 appears to be regulated by TCR peptide affinity and is correlated with vastly different cellular outcomes. The facts that weak stimulation through the TCR results in the activation of Golgi membrane-associated ERK and that under conditions of weak, but not strong, stimulation through the TCR W97ALck fails to support ERK activation suggest that the mislocalized W97ALck mutant is impaired in its ability to phosphorylate Golgi membrane-associated Raf-1.

Our data demonstrate that, compared to WTLck, W97ALck is impaired in its ability to traffic through the Golgi apparatus and to colocalize with Golgi apparatus-associated N-Ras. Thus, in both WTLck- and W97ALck-expressing cells, low-grade stimulation results in normal Golgi apparatus-associated N-Ras activation and presumably normal recruitment of Raf-1. Golgi apparatus-localized WTLck is then able to phosphorylate Raf-1, resulting in its full activation. The decreased association of W97ALck with the Golgi apparatus results in reduced tyrosine phosphorylation of Golgi apparatus-associated Raf-1, which is not sufficient to support the activation of ERK MAP kinase following low-grade stimulation through the TCR. The fact that we did not observe any obvious redistribution of WTLck following low-grade stimulation indicates either that Golgi apparatus-associated Lck becomes activated on Golgi membranes or that plasma membrane-activated Lck traffics to the Golgi apparatus in very low quantities or is accompanied by a translocation of Golgi apparatus-associated Lck back to the plasma membrane. Additional studies are necessary to investigate these possibilities.

Our data support a model whereby strong antigen binding to the TCR triggers ERK activation that is less dependent on Lck-mediated activation of Raf-1 on the Golgi apparatus. Under these conditions, either (i) Lck is needed to initiate TCR signaling but is not required at a distal step in the Ras-Raf-1-ERK signaling complex, as the quantities of partially activated Raf-1 that result from strong binding to the TCR are sufficient to activate ERK, or (ii) the activation of Raf-1 still requires Lck but occurs at the plasma membrane where W97ALck is localized. Under conditions where antigen binding to the TCR is weak, the activation of ERK is mediated by Golgi apparatus-associated N-Ras and is dependent on Golgi apparatus-localized Lck for the tyrosine phosphorylation and full activation of Raf-1. The ability of differentially localized Lck to activate Raf-1 may be important in T-cell development in the thymus, where the strength of signaling through the TCR is critical. It also may have relevance in the periphery, where the immune system needs to respond to the presence of weakly binding antigens. Our data demonstrate a second supporting role for Lck in the activation of the ERK pathway.


   ACKNOWLEDGMENTS
 
We thank Chris Isaacson for performing the in vitro kinase assays, Jennifer Sturgis for providing the confocal imaging, and Shanjin Huang for data analysis and helpful discussions. Flow cytometry and imaging data were acquired in the Purdue Cancer Center Cytometry Laboratories, supported by Purdue Cancer Center NCI CCSG CA23168-28.

This work was supported by Public Health Service grant R01 GM48099 (M.L.H.) from the National Institute of General Medical Sciences. S.S.O. was supported by a Purdue University Research Foundation assistantship.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, Hansen Life Sciences Building, 201 South University Street, West Lafayette, IN 47907. Phone: (765) 494-1442. Fax: (765) 494-9193. E-mail: harrisonm{at}purdue.edu Back

{triangledown} Published ahead of print on 12 November 2007. Back

{dagger} Present address: Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, CA. Back

{ddagger} Present address: Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, IN. Back


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
1. Balan, V., D. T. Leicht, J. Zhu, K. Balan, A. Kaplun, V. Singh-Gupta, J. Qin, H. Ruan, M. J. Comb, and G. Tzivion. 2006. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol. Biol. Cell 17:1141-1153.[Abstract/Free Full Text]

2. Bivona, T. G., I. Perez De Castro, I. M. Ahearn, T. M. Grana, V. K. Chiu, P. J. Lockyer, P. J. Cullen, A. Pellicer, A. D. Cox, and M. R. Philips. 2003. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424:694-698.[CrossRef][Medline]

3. Chiu, V. K., T. Bivona, A. Hach, J. B. Sajous, J. Silletti, H. Wiener, R. L. Johnson II, A. D. Cox, and M. R. Philips. 2002. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4:343-350.[Medline]

4. Chong, H., J. Lee, and K. L. Guan. 2001. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J. 20:3716-3727.[CrossRef][Medline]

5. Chong, H., H. G. Vikis, and K. L. Guan. 2003. Mechanisms of regulating the Raf kinase family. Cell. Signal. 15:463-469.[CrossRef][Medline]

6. Chow, Y. H., K. Pumiglia, T. H. Jun, P. Dent., T. W. Sturgill, and R. Jove. 1995. Functional mapping of the N-terminal regulatory domain in the human Raf-1 protein kinase. J. Biol. Chem. 270:14100-14106.[Abstract/Free Full Text]

7. Daniels, M. A., E. Teixeiro, J. Gill, B. Hausmann, D. Roubaty, K. Holmberg, G. Werlen, G. A. Hollander, N. R. Gascoigne, and E. Palmer. 2006. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 444:724-729.[CrossRef][Medline]

8. Denny, M. F., H. C. Kaufman, A. C. Chan, and D. B. Straus. 1999. The lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling. J. Biol. Chem. 274:5146-5152.[Abstract/Free Full Text]

9. Diaz, B., D. Barnard, A. Filson, S. MacDonald, A. King, and M. Marshall. 1997. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol. Cell. Biol. 17:4509-4516.[Abstract]

10. Dougherty, M. K., J. Muller, D. A. Ritt, M. Zhou, X. Z. Zhou, T. D. Copeland, T. P. Conrads, T. D. Veenstra, K. P. Lu, and D. K. Morrison. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17:215-224.[CrossRef][Medline]

11. Fabian, J. R., I. O. Daar, and D. K. Morrison. 1993. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13:7170-7179.[Abstract/Free Full Text]

12. Goldsmith, M. A., and A. Weiss. 1987. Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor. Proc. Natl. Acad. Sci. USA 84:6879-6883.[Abstract/Free Full Text]

13. Harding, A., T. Tian, E. Westbury, E. Frische, and J. F. Hancock. 2005. Subcellular localization determines MAP kinase signal output. Curr. Biol. 15:869-873.[CrossRef][Medline]

14. Hawash, I. Y., K. P. Kesavan, A. I. Magee, R. L. Geahlen, and M. L. Harrison. 2002. The Lck SH3 domain negatively regulates localization to lipid rafts through an interaction with c-Cbl. J. Biol. Chem. 277:5683-5691. (Erratum, 277:17376).[Abstract/Free Full Text]

15. Hekman, M., A. Fischer, L. P. Wennogle, Y. K. Wang, S. L. Campbell, and U. R. Rapp. 2005. Novel C-Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation. FEBS Lett. 579:464-468.[CrossRef][Medline]

16. Horejsi, V., W. Zhang, and B. Schraven. 2004. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat. Rev. Immunol. 4:603-616.[CrossRef][Medline]

17. Jelinek, T., P. Dent., T. W. Sturgill, and M. J. Weber. 1996. Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol. Cell. Biol. 16:1027-1034. (Erratum, 17:2971, 1997.)[Abstract]

18. Kim, H. K., J. W. Kim, A. Zilberstein, B. Margolis, J. G. Kim, J. Schlessinger, and S. G. Rhee. 1991. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 65:435-441.[CrossRef][Medline]

19. Laakko, T., and R. L. Juliano. 2003. Adhesion regulation of stromal cell-derived factor-1 activation of ERK in lymphocytes by phosphatases. J. Biol. Chem. 278:31621-31628.[Abstract/Free Full Text]

20. Latour, S., and A. Veillette. 2001. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr. Opin. Immunol. 13:299-306.[CrossRef][Medline]

21. Law, C. L., K. A. Chandran, S. P. Sidorenko, and E. A. Clark. 1996. Phospholipase C-{gamma}1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol. Cell. Biol. 16:1305-1315.[Abstract]

22. Lee, K. H., A. D. Holdorf, M. L. Dustin, A. C. Chan, P. M. Allen, and A. S. Shaw. 2002. T cell receptor signaling precedes immunological synapse formation. Science 295:1539-1542.[Abstract/Free Full Text]

23. Ma, H., T. M. Yankee, J. Hu, D. J. Asai, M. L. Harrison, and R. L. Geahlen. 2001. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J. Immunol. 166:1507-1516.[Abstract/Free Full Text]

24. Marais, R., Y. Light, H. F. Paterson, and C. J. Marshall. 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14:3136-3145.[Medline]

25. Mason, C. S., C. J. Springer, R. G. Cooper, G. Superti-Furga, C. J. Marshall, and R. Marais. 1999. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18:2137-2148.[CrossRef][Medline]

26. Mor, A., and M. R. Philips. 2006. Compartmentalized Ras/MAPK signaling. Annu. Rev. Immunol. 24:771-800.[CrossRef][Medline]

27. Palacios, E. H., and A. Weiss. 2004. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23:7990-8000.[CrossRef][Medline]

28. Pathan, N. I., R. L. Geahlen, and M. L. Harrison. 1996. The protein-tyrosine kinase Lck associates with and is phosphorylated by Cdc2. J. Biol. Chem. 271:27517-27523.[Abstract/Free Full Text]

29. Perez de Castro, I., T. G. Bivona, M. R. Philips, and A. Pellicer. 2004. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol. Cell. Biol. 24:3485-3496.[Abstract/Free Full Text]

30. Popik, W., and P. M. Pitha. 1996. Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway. Mol. Cell. Biol. 16:6532-6541.[Abstract]

31. Rudd, M. L., A. Tua-Smith, and D. B. Straus. 2006. Lck SH3 domain function is required for T-cell receptor signals regulating thymocyte development. Mol. Cell. Biol. 26:7892-7900.[Abstract/Free Full Text]

32. Samelson, L. E. 2002. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20:371-394.[CrossRef][Medline]

33. Stokoe, D., and F. McCormick. 1997. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J. 16:2384-2396.[CrossRef][Medline]

34. Straus, D. B., and A. Weiss. 1992. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585-593.[CrossRef][Medline]

35. Wang, Q. M., P. R. Srinivas, M. L. Harrison, and R. L. Geahlen. 1991. Partial purification and characterization of the lck protein-tyrosine kinase from bovine thymus. Biochem. J. 279:567-574.[Medline]

36. Wellbrock, C., M. Karasarides, and R. Marais. 2004. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5:875-885.[CrossRef][Medline]

37. Williams, N. G., T. M. Roberts, and P. Li. 1992. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc. Natl. Acad. Sci. USA 89:2922-2926.[Abstract/Free Full Text]

38. Wong, J., D. Straus, and A. C. Chan. 1998. Genetic evidence of a role for Lck in T-cell receptor function independent or downstream of ZAP-70/Syk protein tyrosine kinases. Mol. Cell. Biol. 18:2855-2866.[Abstract/Free Full Text]

39. Yankee, T. M., L. M. Keshvara, S. Sawasdikosol, M. L. Harrison, and R. L. Geahlen. 1999. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain. J. Immunol. 163:5827-5835.[Abstract/Free Full Text]

40. Zhu, J., V. Balan, A. Bronisz, K. Balan, H. Sun, D. T. Leicht, Z. Luo, J. Qin, J. Avruch, and G. Tzivion. 2005. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. Mol. Biol. Cell 16:4733-4744.[Abstract/Free Full Text]

Molecular and Cellular Biology, January 2008, p. 630-641, Vol. 28, No. 2
0270-7306/08/$08.00+0     doi:10.1128/MCB.00150-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
MCB.00150-07v1
28/2/630    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.
Right arrow Articles by Harrison, M. L.
Right arrow Search for Related Content
PubMed
Right arrow